
CVM
CEL-SCI Corp
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.450
Open
6.780
VWAP
7.58
Vol
945.62K
Mkt Cap
55.93M
Low
6.250
Amount
7.17M
EV/EBITDA(TTM)
--
Total Shares
54.16M
EV
53.78M
EV/OCF(TTM)
--
P/S(TTM)
--
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Show More
Valuation Metrics
The current forward P/E ratio for CEL-SCI Corp (CVM.A) is -0.68, compared to its 5-year average forward P/E of -13.66. For a more detailed relative valuation and DCF analysis to assess CEL-SCI Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-13.66
Current PE
-0.68
Overvalued PE
7.17
Undervalued PE
-34.49
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-5.47
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.94
Undervalued EV/EBITDA
-12.88
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
522.19
Current PS
18.16
Overvalued PS
1797.81
Undervalued PS
-753.43
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
-9.64%
-6.39M
Operating Profit
FY2025Q2
YoY :
-9.28%
-6.57M
Net Income after Tax
FY2025Q2
YoY :
-44.26%
-2.33
EPS - Diluted
FY2025Q2
YoY :
-3.49%
-4.37M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CVM News & Events
Events Timeline
2025-07-11 (ET)
2025-07-11
12:22:42
CEL-SCI announces pricing of $5.7M at-the-market common stock offering

2025-07-11
09:22:45
CEL-SCI teams with Saudi Arabia pharmaceutical, healthcare company for Multikine

2025-05-21 (ET)
2025-05-21
20:37:55
CEL-SCI 2M share Spot Secondary priced at $2.50

Sign Up For More Events
Sign Up For More Events
News
2.0
07-14BenzingaUltragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
7.5
07-14BenzingaWhy Datavault AI Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
8.5
07-11NewsfilterCEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
Sign Up For More News
People Also Watch

LIVE
Live Ventures Inc
16.230
USD
+1.06%

MRNS
Marinus Pharmaceuticals Inc
0
USD
0.00%

PMN
ProMIS Neurosciences Inc
0.987
USD
+8.94%

STBX
Starbox Group Holdings Ltd
0
USD
-9.95%

MTEK
Maris Tech Ltd
3.315
USD
-2.21%

SLGL
Sol Gel Technologies Ltd
11.000
USD
-0.99%

VCIG
VCI Global Ltd
1.230
USD
+36.20%

AKTX
Akari Therapeutics PLC
1.120
USD
+1.82%

DTST
Data Storage Corp
4.680
USD
-7.51%

UBX
UNITY Biotechnology Inc
0
USD
-49.98%
FAQ

What is CEL-SCI Corp (CVM) stock price today?
The current price of CVM is 8.2 USD — it has increased 19.71 % in the last trading day.

What is CEL-SCI Corp (CVM)'s business?

What is the price predicton of CVM Stock?

What is CEL-SCI Corp (CVM)'s revenue for the last quarter?

What is CEL-SCI Corp (CVM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for CEL-SCI Corp (CVM)'s fundamentals?

How many employees does CEL-SCI Corp (CVM). have?
